Clinical effect of intraperitoneal infusion of cisplatin combined with paclitaxel in the treatment of advanced ovarian cancer
Objective To investigate the clinical effect of intraperitoneal infusion of cisplatin combined with paclitaxel in the treatment of advanced ovarian cancer.Methods 46 patients with advanced ovarian cancer were selected and divided into the control group(treated with paclitaxel combined with cisplatin intravenous infusion)and the study group(treated with paclitaxel combined with cisplatin intraperitoneal infusion)by random drawing method,with 23 cases each.The clinical effect of the two groups was compared.Results The total effective rate of 95.65％in the study group was significantly higher than 65.22％in the control group(P＜0.05).The CD4+/CD8+ ratio in the study group was significantly higher than that in the control group,while the CD4+CD25+ratio was significantly lower than that in the control group(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).The improvement rate of serum carbohydrate antigen(CA125)in the study group was significantly higher than that in the control group(P＜0.05).Conclusion In the treatment of advanced ovarian cancer,intraperitoneal infusion of cisplatin combined with paclitaxel is superior to traditional intravenous infusion.
Advanced ovarian cancerPeritoneal perfusionCisplatinPaclitaxelClinical effectImmune index
NETL
NSTL
万方数据
